| DB ID | MyCo_7056 |
| Title | Analysis of serum polyunsaturated fatty acid metabolites in allergic bronchopulmonary aspergillosis |
| Year | 2020 |
| PMID | 32758241 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, with ethics number GYFYY-2016-73. |
| Site of Infection | Lungs |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | HPETE |
| Biomarker Full Name | 15(S)-hydroperoxyeicosatetraenoic acid |
| Biomarker Type | Diagnostic |
| Biomolecule | Metabolite |
| Geographical Location | China |
| Cohort | This is a retrospective study by using data from the Allergy Information Repository of State Key Laboratory of Respiratory Disease in China. We enrolled 12 patients with ABPA, 23 patients with allergic asthma and 12 healthy controls from the First Affiliated Hospital of Guangzhou Medical University. The diagnosis of ABPA was based on the criteria of the International Society for Human and Animal Mycology (ISHAM) working Group. |
| Cohort No. | 35 Patients and 12 Control |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder that results from immune hypersensitivity to Aspergillus fumigatus (A. fumigatus) colonizing the airways, which is common among patients with asthma and cystic fibrosis. It is charac- terized by a Th2 bias immune response, peripheral blood and pulmonary eosinophilia, increased total serum IgE, increased A. fumigatus sIgE and sIgG. The pathogenesis of ABPA remains unclear. By 2013, there are estimated 4.8 million ABPA patients worldwide and the prevalence of ABPA in adults with asthma was 2.5% (range 0.72–3.5%). However, due to diverse and atypical clinical manifestations, ABPA is easily misdiagnosed and missed by clinicians. There are also limited drugs for the treatment of ABPA. Glucocorticoids and antifungal agents are mainly used clinically, which is associated with numerous side effects. Therefore, it is crucial to identify specific mechanisms and therapies in ABPA. |
| Technique | Liquid chromatography |
| Analysis Method | UHPLC-Q-TOF/MS analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | UHPLC-Q-TOF/MS analysis |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
